Tech Company Financing Transactions
Excelimmune Funding Round
Excelimmune closed a $1 million Series B funding round on 2/11/2010. Investors included private investors.
Transaction Overview
Company Name
Announced On
2/11/2010
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to continue studies of the company's first drug candidate, Staphguard, a human recombinant polyclonal antibody (HRPA) against methicillin-resistant Staphylococcus aureus (MRSA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1776 Massachusetts Ave.
Lexington, MA 02420
USA
Lexington, MA 02420
USA
Phone
Website
Email Address
Overview
Excelimmune is a biopharmaceutical company developing fully human recombinant polyclonal antibodies for therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elizabeth Reczek
Chief Financial Officer
Jason Walsh
VP - Product Management
Thomas Dahl
Browse more venture capital transactions:
Prev: 2/11/2010: TuneSat venture capital transaction
Next: 2/11/2010: Zenverge venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs